drugset / Trial / NCT04313634
Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans
RandomizedParallel-groupOpen-labelSupportive care
Summary
To determine if senolytic drugs reduce senescent cell burden and reduce bone resorption markers/increase bone formation markers in elderly women.
Timeline
- Start
- 2020-06-09
- Primary completion
- 2023-06-06
- Completion
- 2023-06-06
Publications
- Farr JN, Monroe DG, Atkinson EJ, Froemming MN, Ruan M, LeBrasseur NK, Khosla S. Characterization of Human Senescent Cell Biomarkers for Clinical Trials. Aging Cell. 2025 May;24(5):e14489. doi: 10.1111/acel.14489. Epub 2025 Jan 17.
- Farr JN, Atkinson EJ, Achenbach SJ, Volkman TL, Tweed AJ, Vos SJ, Ruan M, Sfeir J, Drake MT, Saul D, Doolittle ML, Bancos I, Yu K, Tchkonia T, LeBrasseur NK, Kirkland JL, Monroe DG, Khosla S. Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial. Nat Med. 2024 Sep;30(9):2605-2612. doi: 10.1038/s41591-024-03096-2. Epub 2024 Jul 2.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fisetin | Small molecule | 20 mg/kg | Oral |
| Subject | Quercetin | Small molecule | 1000 mg | Oral |
| Subject | dasatinib anhydrous | Small molecule | 100 mg | — |
Indications
No indication recorded.